This is the protocol for a review and there is no abstract. The objectives are as follows:
The primary objective of this review will be to evaluate the efficacy and safety of early treatment with GA or IFN beta on proportion of CIS patients delayed to convert to MS.
Secondary objectives will be:
1. In those patients who develop CDMS to asses the time to second relapse and the annual relapse rate.
2. To assess the effect on surrogate markers of disease activity, such as MRI occurrence of new active lesions or changes of disease burden.
If you can't find a tool you're looking for, please click the link at the top of the page to "Go to old article view". Alternatively, view our Knowledge Base articles for additional help. Your feedback is important to us, so please let us know if you have comments or ideas for improvement.